dsip
DSIP, explained.
DSIP — delta sleep-inducing peptide — is a naturally occurring neuropeptide that has been studied in the context of sleep regulation. This page is a neutral, educational overview of what it is, how researchers think it works, and its regulatory status. It is not medical advice and does not recommend use.
Educational only — not medical advice.
DSIP (delta sleep-inducing peptide) is a naturally occurring 9-amino-acid neuropeptide first isolated from sleeping rabbits in 1977 and named for its association with deep, delta-wave sleep. Human evidence is limited, old, and conflicting, and it is not FDA-approved — it is sold only as a research chemical. This page is a neutral educational overview.
What DSIP is
DSIP stands for delta sleep-inducing peptide — a small neuropeptide made of just nine amino acids (sequence WAGGDASGE). It was first isolated in 1977 by Schoenenberger and Monnier from the blood of rabbits driven into sleep by electrical stimulation of the thalamus, and it was named for its association with delta-wave — that is, deep — sleep. DSIP occurs naturally in the brain and other tissues, and for decades it has been studied as a possible endogenous sleep-regulating signal. Despite an evocative name and a lot of early interest, the literature never established exactly what DSIP does — its precise role, its receptor, and even whether it truly merits the title 'sleep peptide' all remain unsettled. DSIP is not an approved drug anywhere; anything sold under its name today is an unapproved research chemical.
How DSIP is thought to work
DSIP's mechanism is not well established, so what follows is theory drawn mostly from animal and lab studies rather than settled fact. The central hypothesis is sleep modulation: in some animal models DSIP appears to shift the brain toward delta-wave (slow-wave) sleep. It has been described in the literature less as a sedative and more as a modulator — with reported effects that are stronger when sleep is already disturbed and minimal in healthy, well-rested subjects. Beyond sleep, early work pointed to possible influences on stress hormones (including ACTH) and thermoregulation, and to proposed antioxidant or neuroprotective signaling, but none of these are established. A major gap underlies all of it: no specific DSIP receptor has ever been conclusively identified. Whether circulating DSIP actually causes sleep or merely accompanies it has never been firmly resolved.
Areas of research interest
- Deep, slow-wave sleep — the original animal finding and the source of its name
- Sleep in disturbed-sleep models — where small, old human studies have been conducted, with weak and conflicting results
- Endogenous sleep signaling — how a natural 'sleep peptide' might fit into the body's own sleep regulation
- Stress, pain, and withdrawal pathways — early preclinical reports, not established in humans
- Thermoregulation and neuroprotection — proposed in early studies, not established
Safety & legal status
The honest headline on safety is how little is known: the few human studies were short and small, so the central issue is missing long-term data rather than any clean bill of health. Where side effects were noted in those studies, they were generally mild and transient — headache, nausea, and a touch of vertigo — and because DSIP is distributed as an unregulated research chemical, the contents of a given vial can vary from one supplier to the next. On the legal side, DSIP is not FDA-approved and carries no recognized therapeutic status; it is treated as research-only and is not permitted to be marketed for human use, though it does appear on the FDA Pharmacy Compounding Advisory Committee's July 2026 agenda (as Emideltide) for possible 503A compounding eligibility — which is a different matter from drug approval. None of this is medical advice; consult a qualified licensed provider about your own situation.
DSIP vs Thymosin Alpha-1
| DSIP | Thymosin Alpha-1 | |
|---|---|---|
| What it is | Natural 9-amino-acid sleep-linked neuropeptide | Immune-modulating peptide |
| Evidence level | Preclinical — weak, conflicting human data | Clinically validated, far stronger evidence |
| Approval status | Not approved; research-only | An approved immune peptide in some regions |
| Primary research interest | Deep sleep / sleep regulation | Immune signaling |
| Mechanism clarity | No defined receptor; mechanism uncertain | Better-characterized immune mechanism |
Frequently asked
What are DSIP's reported side effects?+
Human safety data is sparse and short-term. Some human studies reported transient headache, nausea, and vertigo, with few other acute effects noted. There are no long-term safety studies, and because DSIP is sold as an unregulated research chemical, purity and identity vary. The larger limitation is simply how little is known. This is not medical advice.
What does the research on DSIP look at?+
DSIP has been studied primarily in the context of deep, delta-wave sleep — that association is the reason for its name. A few small, decades-old human studies examined disturbed sleep, but the evidence overall is weak and conflicting. This describes the research interest only and is not a claim of benefit or a recommendation.
Is DSIP a steroid?+
No. DSIP is a naturally occurring 9-amino-acid neuropeptide, not an anabolic steroid. Its human data is sparse and short-term, with no long-term studies, so it cannot be characterized as proven safe. None of this is medical advice; consult a qualified licensed provider.
Is DSIP FDA approved?+
No. DSIP is not FDA-approved and has no recognized therapeutic status — it is sold only as a research chemical. It is on the FDA Pharmacy Compounding Advisory Committee's July 2026 agenda (as Emideltide) for possible 503A compounding eligibility, but that would not be drug approval, and marketing it for human use is not permitted.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more